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ABSTRACT 
Most algorithms for type 2 diabetes mellitus (T2DM) do not recommend treatment escalation 
until glycated haemoglobin (HbA1c) fails to reach the recommended target of 7% (53 
mmol/mol) within approximately 3 months on any treatment regimen (‘treat to failure’). Clinical 
inertia and/or poor adherence to therapy contribute to patients not reaching glycaemic targets 
when managed according to this paradigm. Clinical inertia exists across the entire spectrum of 
anti-diabetes therapies, although it is most pronounced when initiating and optimizing insulin 
therapy. Possible reasons include needle aversion, fear of hypoglycaemia, excessive weight 
gain and/or the need for increased self-monitoring of blood glucose. Studies have suggested, 
however, that early intensive insulin therapy in newly diagnosed, symptomatic patients with 
T2DM with HbA1c >9% (75 mmol/mol) can preserve beta-cell function, thereby modulating the 
disease process. Furthermore, postprandial plasma glucose (PPG) is a key component of 
residual dysglycaemia, evident especially when HbA1c remains above target despite fasting 
normoglycaemia. Therefore, to achieve near normoglycaemia, additional treatment with 
prandial insulin or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) is often required. 
Long- or short-acting GLP-1 RAs offer effective alternatives to basal or prandial insulin in 
patients inadequately controlled with other therapies or basal insulin alone, respectively. This 
review highlights the limitations of current algorithms and proposes an alternative based on the 
early introduction of insulin therapy and the rationale for the sequential or fixed combination of 
GLP-1 RAs with insulin (‘treat-to-success’ paradigm). 
 
Keywords: insulin therapy, GLP-1, type 2 diabetes mellitus, treatment algorithm 
REVIEW ARTICLE 
 
4 
 
1 │ INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is a complex, metabolic and progressive disease commonly 
associated with diverse pathophysiology, which is characterized by relative insulin insufficiency 
and insulin resistance leading to excessive hepatic glucose production, and fasting and 
postprandial hyperglycaemia.1,2 In clinical practice, this manifests as a broad phenotypic 
expression due to patients presenting at different stages in the natural history of the disease. 
Pancreatic beta-cell dysfunction is critical to disease development,2 and insulin resistance in 
the liver and peripheral target tissues also has a central role in the development of 
cardiometabolic changes.3 Genetic susceptibility to T2DM is also an important factor as many 
genes interact with environmental factors, which, in turn, affect downstream pathways, 
resulting in the heterogeneous nature of the disease.4 
The currently available glucose-lowering agents are reviewed, and guidance for 
clinicians on treatment choices based on an individual patient-centred approach is provided, in 
guidelines published by the European Association for the Study of Diabetes (EASD), American 
Diabetes Association (ADA), American Association of Clinical Endocrinology (AACE), 
American College of Endocrinology (ACE), and International Diabetes Federation.5-7 The 
advised treatment target is generally glycated haemoglobin (HbA1c) ≤7% (53 mmol/mol), seen 
as indicative of good control. Among patients in the US diagnosed with T2DM, only 52% have 
HbA1c <7% (53 mmol/mol), while 13% have values >9% (75 mmol/mol). Indeed, only 14% of 
individuals achieve recognized targets for glucose, blood pressure and lipids (alongside non-
smoking status).8 Of considerable concern, in Eastern Europe, Latin America and Asia, 36% of 
patients with T2DM have never had their HbA1c measured; among those with measurements, 
36% achieved HbA1c <7% (53 mmol/mol) and only 3.6% achieved all three recommended 
targets for glucose, blood pressure and low-density lipoprotein cholesterol.9 Possible reasons 
for these poor results include poor understanding of the disease and its potential 
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consequences, as well as the necessary lifestyle changes and available treatment options, all 
of which contribute to non-compliance. In addition, the lack of agreement among healthcare 
providers regarding the value, and hence the proper application, of self-monitoring of blood 
glucose (SMBG) can be a compounding factor. 
Initial pharmacotherapy is generally metformin introduced at, or soon after, diagnosis in 
conjunction with diet and lifestyle changes. Alternative therapies are recommended if the 
patient is intolerant to metformin or its use is contraindicated.7,10 Where monotherapy does not 
achieve or sustain the mutually agreed HbA1c target after approximately 3 months, treatment 
will need to be advanced, with a number of options advocated as second-line therapies. These 
include agents within the following categories: sulphonylurea, thiazolidinedione, alpha-
glucosidase inhibitor, dipeptidyl peptidase-4 (DPP-4) inhibitor, glucagon-like peptide-1 receptor 
agonist (GLP-1 RA), sodium-glucose co-transporter-2 (SGLT-2) inhibitor and basal insulin.7 
These options can be tailored according to a patient’s treatment needs and disease 
characteristics. In patient populations with elevated cardiovascular risk, the cardiovascular 
(CV) outcome trials (CVOTs) LEADER (liraglutide), EMPA-REG (empagliflozin) and SUSTAIN 
6 (semaglutide) all showed a reduction in cardiovascular events (according to the primary 3-
point MACE).11-13 In contrast to the GLP-1 RAs, treatment with empagliflozin was associated 
with a reduction in cardiovascular death from early in the trial suggesting a haemodynamic 
mechanism. This is supported by the significant reduction in hospitalization due to heart failure 
in this study. 13 The National Institute for Health and Care Excellence advocates continuation of 
current therapy until the patient no longer meets the desired target (HbA1c 7.5% [58 
mmol/mol]), and only then should further options be considered, i.e. a ‘treat-to-failure’ 
approach.10  
For patients who do not reach target HbA1c after 3 months, clinicians are encouraged 
to discuss the aforementioned second-line treatment classes, usually in combination with 
metformin, with the choice of treatment being dependent on patient preference and disease 
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status.7 Basal insulin or premixed insulin formulations are often not considered until advanced 
disease when patients do not achieve target HbA1c despite intensive treatment with a single or 
a combination of anti-diabetes therapy. There is, however, evidence demonstrating that the 
early introduction of intensive insulin therapy (first-line), especially in those with an HbA1c >9% 
(75 mmol/mol; usually symptomatic with a short disease history), positively influences 
glycaemic control, maintenance of beta-cell function and rates of remission (many patients 
maintaining optimum glycaemic control for at least 12 months).2 Basal insulin alone has also 
obtained similar responses to continuous insulin infusion (CSII) in an equivalent setting.14 In 
cases where basal insulin has been up-titrated to achieve a near-normal fasting plasma 
glucose (FPG) yet HbA1c remains above target, a short-acting GLP-1 RA or prandial insulin 
can be added to reduce postprandial plasma glucose (PPG) excursions.7 In patients with 
HbA1c >9% (75 mmol/mol; with/without symptoms), EASD/ADA and AACE/ACE guidelines 
advocate first-line combination therapy over sequential treatment.5,7 However, there remains a 
considerable delay in progressing treatment in clinical practice.15 
Most patients with T2DM require multiple treatments to maintain adequate glycaemic 
control. For example, in the UK Prospective Diabetes Study, about 50% of patients with newly 
diagnosed T2DM maintained HbA1c <7% (53 mmol/mol) with monotherapy for 3 years, 
although only about 25% achieved this glycaemic target with monotherapy after 9 years.16 
Even with basal insulin treatment, a significant proportion of patients continue to have an 
HbA1c above target.17 
This review considers the limitations of the current treatment algorithms and proposes 
an alternative paradigm based around the early introduction of insulin therapy (especially, 
based on available evidence, in those with high HbA1c) and combination therapy with a GLP-1 
RA.  
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2 │ CURRENT TREATMENT LANDSCAPE  
T2DM is often inadequately controlled despite the availability of numerous injectable and oral 
anti-diabetic drugs (OADs) supported by a variety of treatment guidelines. Between 24% and 
54% of patients treated with basal insulin do not achieve HbA1c ≤7%, despite meeting target 
FPG levels.18 
Clinical inactivity, ‘inertia’, among healthcare professionals, and poor patient adherence 
to therapy are among the major reasons why many patients do not reach their glycaemic target 
when adopting current treatment paradigms, i.e. therapy is not intensified despite poor 
glycaemic control on an existing regimen.19,20 Furthermore, numerous studies (in the US and 
Europe) suggest that clinical inertia is unacceptably common in the management of T2DM.20-22 
Brown and colleagues reported that, on average, patients accumulated approximately 10 
years’ excess glycaemic burden with HbA1c >7% (53 mmol/mol) from diagnosis until 
beginning insulin treatment.15 This may have a significant impact on disease severity and risk 
of micro- and macrovascular complications.23 
Several factors can potentially contribute to clinical inertia and poor patient adherence 
to therapy: the introduction of newer, more complicated and expensive therapies compounded 
by inadequate educational support, which will undoubtedly influence the time taken for 
clinicians to become acquainted with these treatments. To date, there are few head-to-head 
cost–benefit comparisons between the ever-increasing number of newer treatments available 
to assist clinicians in making informed decisions. Tolerability is also a major factor, e.g. insulin 
and sulphonylureas are associated with hypoglycaemia and weight gain; thiazolidinediones 
with increased risk of weight gain, oedema, heart failure and bone fractures; SGLT-2 inhibitors 
with genitourinary infections, polyuria, volume depletion, hypotension, dizziness, increased 
low-density lipoprotein cholesterol, transient increases in creatinine, increased risk of bone 
fractures24 and non-hyperglycaemic ketoacidosis.25 GLP-1 RAs induce transient 
gastrointestinal (GI) intolerance in the majority of patients, although <10% of individuals 
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discontinue treatment due to any adverse event.26 It is also becoming increasingly recognized 
that there is considerable variation in patients’ response to anti-diabetes therapy, which can be 
explained by genetic differences (e.g. for metformin, sulphonylureas and incretin-based 
therapies).27,28 
Despite a growing number of treatments, 5–10 years after diagnosis, most patients will 
eventually require insulin therapy to achieve their glycaemic target.29 Clinical inertia is most 
pronounced when introducing insulin30 and may relate to a number of factors, including fear of 
hypoglycaemia and excessive weight gain,31,32 together with the need for structured education 
including SMBG.33 In the START study of patients with stable but poorly controlled T2DM, a 1 
unit/day self-titration bolus insulin algorithm to reach a target 2-hour PPG of 5.0–8.0 mmol/L 
was seen to be as effective as a physician-managed algorithm.34 Similar results were reported 
in a study of 4961 patients with poorly controlled T2DM who initiated and titrated insulin 
according to either an investigator- or a self-led algorithm.35 In this study, patients using the 
self-led algorithm experienced greater decreases in HbA1c versus patients whose insulin 
treatment was investigator led (p < 0.001), and there was no significant difference in the 
occurrence of severe hypoglycaemia between the two groups.35 Of note, even though there is 
some unity and agreement between the current treatment algorithms,36 algorithm-driven insulin 
use in advanced T2DM is often associated with a greater incidence of hypoglycaemia and 
weight gain than when initiated earlier in the course of disease.30 In a pooled analysis of 11 
prospective trials, early use of insulin in combination with metformin resulted in less weight 
gain and symptomatic hypoglycaemia compared with insulin added to two OADs (reflective of 
treatment later in the disease course).37 
The issues discussed above highlight the need to re-consider the current treatment 
algorithms for the management of patients with T2DM. Alternative approaches include the 
early initiation of insulin therapy with the addition of a GLP-1 RA when appropriate. This option 
raises the prospect of improved success in achieving glycaemic targets sooner and 
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maintaining them for longer than with the conventional approach, while reducing the risk of 
hypoglycaemia and mitigating weight gain due to lower doses of the individual components. 
 
3 │ THE CASE FOR THE EARLY INTRODUCTION OF INSULIN THERAPY 
Studies have suggested that the introduction of intensive insulin treatment in patients 
presenting with even moderately high HbA1c (median of 7.2%) can alter the progressive 
nature of T2DM by reversing the adverse impact of glucotoxicity and lipotoxicity on beta-cell 
function and insulin sensitivity.38 In patients with newly diagnosed T2DM (mean baseline 
HbA1c ≥9.5% [80 mmol/mol]), both CSII and multiple daily insulin (MDI) injections increased 
target glycaemia attainment in less time than with OADs 2. Markers of beta-cell secretion also 
improved more dramatically following early and intensive insulin therapy.2 Furthermore, rates 
of remission were increased with CSII and MDI injections versus OADs. In a separate study,39 
a greater proportion of patients newly diagnosed with T2DM (HbA1c ≥9% [75 mmol/mol]) 
achieved glycaemic targets with a combination of an OAD plus insulin in less time than with 
OADs alone. Following 1 year of treatment, more patients maintained target glycaemia with an 
OAD plus insulin than with OADs alone and maintained beta-cell function more effectively than 
when OADs were employed solely.39  
A recent 21-year update to a study that treated patients with T2DM and 
microalbuminuria (mean disease duration ~6 years) over 7.8 years with an intensive, 
multifactorial step-wise approach (including dietary changes followed by OADs stepping up to 
Neutral Protamine Hagedorn insulin and multiple insulin injections in patients failing to achieve 
stringent blood pressure, HbA1c and cholesterol targets as well as behavioural approaches) 
versus a conventional treatment approach reported a marked legacy effect on CV outcomes 
with intensive early treatment of these risk factors.40 Significantly fewer patients receiving the 
early intensive intervention died during the follow-up period compared with those treated 
conventionally (p = 0.005); the former group also had 8.1 years longer before experiencing a 
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CV event (p = 0.001) and lived 7.9 years longer than the conventional cohort.40 A post hoc 
analysis of the LIBRA (LIraglutide and Beta cell RepAir) trial identified that the most important 
factor in improving outcomes is the duration of disease at the initiation of intensive treatment.41 
In LIBRA, 25 patients with T2DM for ≤7 years received 4 weeks’ intensive insulin therapy to 
achieve fasting glucose <6.94 mmol/L followed by placebo for 48 weeks. Rates of remission 
(HbA1c <6.5% [48 mmol/mol] and no medication during the 48-week placebo period) were 
78%, 71% and 58% in patients with T2DM of <1, 2 and 3 years’ duration, respectively, and 
loss of remission was slower in patients with disease duration of <2 years versus those with a 
more established disease.41 
In a population-based study, the best HbA1c reductions were observed when basal 
insulin was introduced directly after failure of metformin monotherapy,37 while the improvement 
of HbA1c was less marked when basal insulin was added only after combinations of OADs had 
failed. This demonstrates that a better response to basal insulin can be expected in the earlier 
stages of T2DM.37 Aside from glycaemic control, the additional anti-inflammatory and anti-
oxidant properties of insulin may also help to protect against endothelial dysfunction and 
consequent vascular disease.23,42 Nevertheless, even in cases where early insulin treatment 
has been shown to be beneficial (symptomatic, markedly hyperglycaemic, newly diagnosed 
T2DM), such treatment may not be applied due to the perceived increased work load for the 
patient as well as healthcare professionals. However, studies show that the improvements in 
glycaemic control, beta-cell function and plasma lipid profiles associated with basal insulin 
monotherapy are comparable with those seen with CSII. Therefore, there is the option of a less 
complex basal insulin regimen in patients newly diagnosed with T2DM.14 
When OADs fail to control glycaemia, adding basal insulin predominantly targets FPG, 
which reflects the reduction of overnight hepatic glucose production and suppression of free 
fatty acid release by adipose tissue.29 Several randomized studies have shown that the 
decrements in HbA1c are linearly related to insulin dose (approximately 0.5% decrease in 
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percentage HbA1c for each increase in insulin dose equivalent to 0.1 U/kg/day up to 0.5 
U/kg).43 Above this dosing threshold, the improvement in HbA1c is halved (0.5% decrease in 
percentage HbA1c for each increase in insulin dose of 0.2 U/kg/day). Weight gain, however, 
increases linearly throughout the dose range.44 
Patients with T2DM typically exhibit substantial PPG excursions early in the evolution 
of the disease, which is why basal insulin monotherapy, despite achieving near-normal FPG 
levels, fails to normalize HbA1c in approximately 30% of patients;45 as T2DM progresses, 
defects in PPG are quickly followed by fasting hyperglycaemia due to the dawn 
phenomenon.46,47 Therefore, as PPG can be a significant contributor to overall hyperglycaemia 
at lower levels of HbA1c,46 reducing postprandial excursions is particularly important in 
patients with relatively modest HbA1c elevations or when no further improvement in FPG is 
feasible with basal insulin. Despite adequate basal insulin dose titration, a substantial 
proportion of patients on basal insulin therapy will require additional treatment with either a 
prandial insulin or a GLP-1 RA to address PPG and further improve HbA1c.7 While prandial 
insulin is routinely added to basal insulin in a three-times-daily basal-bolus approach, it has 
been found that a once- or twice-daily regimen can achieve similar HbA1c reductions, with a 
lower risk of hypoglycaemia.48 The hypoglycaemia risk associated with increments in insulin 
doses highlights the need for treatments that augment glycaemic control, but which carry 
limited additional risk of hypoglycaemia.  
 
3.1 │ Rationale for GLP-1 RA therapy 
Native GLP-1 is secreted to augment insulin secretion and suppress glucagon release 
primarily in response to a nutrient challenge. In the circulation, it is quickly degraded (within 2–
3 minutes).49 GLP-1 RAs have been developed that are capable of resisting degradation, 
therefore providing longer in vivo actions with the added possibility of reduced insulin doses 
when used in combination while preventing weight gain and lowering the risk of hypoglycaemia 
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compared with insulin monotherapy.49 Numerous studies confirm the potency of GLP-1 
RAs,26,50 including a systematic literature review and meta-analysis of 15 randomized 
controlled studies that compared GLP-1 RAs plus basal insulin with other anti-diabetes 
treatments.51 GLP-1 RAs, therefore, offer an effective, alternative treatment for T2DM, 
introduced either before or after the initiation of basal insulin or in combination with basal 
insulin.52-56 The combination improves glycaemic control irrespective of whether a GLP-1 RA is 
added to basal insulin or vice versa.  
GLP-1 RAs, based on their differential pharmacokinetic/pharmacodynamic 
characteristics, can be classified as short acting/‘prandial’ (e.g. exenatide, lixisenatide) or long 
acting/‘non-prandial’ (e.g. liraglutide, exenatide [long-acting release], albiglutide, dulaglutide, 
semaglutide).49,57 The short-acting GLP-1 RAs predominantly lower PPG by slowing gastric 
emptying and inhibiting glucagon secretion, whereas the long-acting GLP-1 RAs predominantly 
act on FPG by stimulating insulin secretion.49 In contrast to the short-acting GLP-1 RAs, which 
sustain the delay in gastric emptying over time, continuous infusion of endogenous GLP-1 or 
long-acting GLP-1 RAs induces tachyphylaxis.49  
The currently available GLP-1 RAs allow different patterns of administration, ranging 
from twice daily to once weekly, providing a flexibility in patient treatment options around their 
differing pharmacological properties (Table 1). For example, short-acting/prandial GLP-1 RAs 
might be used once or twice daily58 before the main meal(s) in addition to insulin therapy.  
In addition to their effects on glycaemic control, hypoglycaemia and weight, it is 
important to consider the effects of the GLP-1 RAs on the CV and other systems. The GLP-1 
receptor is widely expressed throughout the body, including the heart (predominantly in the 
sino-atrial node59), and GLP-1 has been demonstrated to have neuroprotective properties, e.g. 
crosses the blood–brain barrier, enhances neurogenesis and reduces the chronic inflammatory 
responses in the brain.60 Incretin-based therapies, i.e. GLP-1 RAs and DPP-4 inhibitors, 
reportedly exert cardio-protective effects, including positively influencing cardiac function (in 
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vitro and animal data), and improving endothelial function (human data).61 In clinical trials, 
however, the CV effects of the individual GLP-1 RAs appear to vary. For example, a meta-
analysis of 60 trials comparing GLP-1 RAs with placebo, insulin and sulphonylureas has 
reported that GLP-1 RAs decreased systolic blood pressure by 1.84–4.60 mmHg.62 However, 
of note, exenatide (2 mg once weekly) and liraglutide (1.2 and 1.8 mg once daily) increased 
the heart rate by 2.06–3.35 beats per minute (bpm) versus placebo.62 After 8 weeks’ treatment 
with lixisenatide or liraglutide, 24-hour mean heart rate was measured using a 24-hour 
ambulatory monitor. Treatment with liraglutide resulted in a clinically significant increase in 
mean 24-hour heart rate by approximately 9 bpm (compared with 3 bpm with lixisenatide).63 
The clinical significance of these changes in heart rate are unclear and need further 
investigation64 in view of the findings from the ELIXA, LEADER and SUSTAIN-6 studies.11,12,65 
As mentioned above, CV outcomes and long-term safety have been investigated in 
three large, recently published trials with liraglutide, lixisenatide and semaglutide.11,12,65 The 
effects of the short-acting GLP-1 RA lixisenatide on CV outcomes were investigated in the 
ELIXA trial, which included >6000 patients with T2DM who had recently experienced an acute 
coronary event and who were at the highest level of CV risk. Primary endpoint events (CV 
death, myocardial infarction, stroke or hospitalization for unstable angina) occurred in 13.4% 
and 13.2% of patients given lixisenatide and placebo, respectively, indicating that lixisenatide 
was non-inferior to placebo for these outcomes (hazard ratio [HR]: 1.02; 95% confidence 
interval [CI]: 0.89–1.17; p < 0.001). Adding lixisenatide to usual care had no significant impact 
on the rate of major CV events over a median follow-up period of 2.1 years.65 The long-term 
CV safety of the long-acting GLP-1 RA liraglutide (versus placebo) was investigated in the 
LEADER study in >9000 adults with T2DM at high risk of major adverse CV events. Median 
follow-up was 3.8 years. In the time-to-event analysis, the rate of the first occurrence of death 
from CV causes, non-fatal myocardial infarction or non-fatal stroke (primary outcome) was 
significantly lower with liraglutide compared with placebo (13% versus 14.9%; HR: 0.87; 95% 
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CI: 0.78–0.97; p < 0.001) and fewer patients died from CV causes with liraglutide compared 
with placebo (4.7% versus 6.0%, respectively; HR: 0.78; 95% CI: 0.66–0.93; p = 0.007).11 In 
the SUSTAIN-6 study of 3297 patients with T2DM given 0.5 or 1.0 mg semaglutide per week 
versus placebo (median follow-up 2.1 years), the proportion of patients with first occurrence of 
CV death, non-fatal myocardial infarction or non-fatal stroke was 6.6% versus 8.9% with either 
semaglutide dose versus placebo, respectively (HR: 0.74; 95% CI: 0.58–0.95; p < 0.001). The 
rate of CV death was comparable in both treatment groups in SUSTAIN-6 (semaglutide 2.7%, 
placebo 2.8%; HR: 0.98; 95% CI: 0.65–1.48; p = 0.92).12  
Differences in the populations recruited and study designs make it difficult to compare 
the findings of ELIXA, LEADER and SUSTAIN-6 directly. The LEADER study had greater 
statistical power and was extended over a longer period compared with ELIXA and SUSTAIN-
6, while the liraglutide and semaglutide CV outcomes studies included patients with higher 
baseline HbA1c compared with those in the lixisenatide CV trial (8.7% [LEADER and 
SUSTAIN-6] versus 7.6% [ELIXA]). Furthermore, HbA1c in the LEADER control group 
remained close to 8% (64 mmol/mol) throughout the study, which may have led to a between-
group difference in HbA1c that varied over time from >1% to 0.4% at 36 months. In addition, 
patients in the ELIXA study all had established CV disease (myocardial infarction or 
hospitalized for unstable angina within 180 days prior to enrolment) and were at a much higher 
risk of further CV events than those in LEADER and SUSTAIN-6. Overall, these large CV 
outcomes studies clearly demonstrate that these particular GLP-1 RAs do not exacerbate CV 
disease and some exhibit cardioprotective properties. It will be interesting to see what findings 
will emerge with the remaining GLP-1 RAs still under investigation (exenatide long-acting 
release, dulaglutide, albiglutide). 
 
3.2 │ GLP-1 RA therapy in combination with insulin therapy 
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Combining basal insulin with a short-acting GLP-1 RA that predominantly lowers PPG is a 
logical management approach when the former fails to achieve adequate glycaemic control 
even when optimally titrated.49 Long-acting GLP-1 RAs, used in combination with basal insulin, 
result in comparable HbA1c reductions with weight loss and lower hypoglycaemia risk when 
compared with basal insulin alone.66,67 Recently, combining GLP-1 RAs (short or long acting) 
and insulin in a single injection (lixisenatide plus insulin glargine, liraglutide plus insulin 
degludec) has been shown to result in a larger glycaemic reduction than when using basal 
insulin alone, reflecting their distinct complementary glucose-lowering mechanisms.68,69 This 
combination increases the proportion of patients who reach target HbA1c while mitigating 
some of the side effects observed with basal bolus insulin regimes.7  
The short-acting GLP-1 RA lixisenatide has been investigated in a series of 
multinational, Phase III trials, (GetGoal clinical trial programme) across a spectrum of patients 
with T2DM. This programme included the GetGoal Duo-1 study, which enrolled patients with 
HbA1c 7–10% (53–86 mmol/mol) despite OADs55; the GetGoal-L trial, with patients 
inadequately controlled on basal insulin54 and the GetGoal-L-Asia trial, which included Asian 
patients with T2DM inadequately controlled with basal insulin with/without sulphonylureas.70 
Figures 1 and 2 illustrate the findings for lixisenatide and liraglutide when added to basal 
insulin. A meta-analysis of five studies encompassing 1184 patients compared lixisenatide and 
once-daily, rapid-acting insulin when added to basal insulin.71 Patients taking lixisenatide were 
approximately twice as likely to reach composite outcomes, i.e. HbA1c <7% (53 mmol/mol) 
and no symptomatic hypoglycaemia (odds ratio [OR]: 1.90), HbA1c <7% (53 mmol/mol) and no 
severe hypoglycaemia (OR: 1.97), and were almost three times more likely to achieve the 
composite outcome of HbA1c <7% (53 mol/mol), no weight gain and no documented 
symptomatic hypoglycaemia (p = 0.0046). Large multinational, Phase III clinical development 
studies have also been carried out to investigate the safety and efficacy of the other GLP-1 
RAs, e.g. the liraglutide LEAD, exenatide DURATION, dulaglutide AWARD, semaglutide 
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SUSTAIN and albiglutide HARMONY programmes.66,72-75 These extensive programmes have 
helped establish the efficacy and safety/tolerability profile of GLP-1 RAs in a range of people 
with T2DM, including those who are treatment-naïve, failing oral agents and treated with GLP-
1RAs as an adjunct to basal insulin. 
Adding GLP-1 RAs to basal insulin achieves similar or greater reductions in HbA1c 
when compared with basal insulin and prandial insulin combinations.7 In the GetGoal Duo-2 
trial, involving patients with inadequate glycaemic control on basal insulin despite continued 
titration, the addition of lixisenatide resulted in similar HbA1c reductions but less 
hypoglycaemia (symptomatic and nocturnal) and less weight gain when compared with once or 
thrice daily prandial insulin (glulisine).76 Furthermore, PPG was significantly reduced with 
lixisenatide compared with both glulisine regimens, although, as expected, transient nausea, 
vomiting and diarrhoea events were more common with lixisenatide.76 These findings suggest 
that a short-acting GLP-1 RA, such as lixisenatide, could be a preferred intensification 
treatment option compared with prandial insulin when a basal insulin regimen is found to be 
insufficient.  
 
3.3 │ Fixed-ratio combinations of basal insulin and GLP-1 RAs 
Combining insulin and incretin therapy is suggested as a treatment option in the EASD/ADA 
guidelines.7 Titratable fixed-ratio combinations (FRCs) of basal insulin and GLP-1 RA are now 
available for single, daily administration. The FRC of insulin glargine 100 U and lixisenatide 
(iGlarLixi) delivers increments of insulin glargine up to a daily maximum dose of 60 U and 
lixisenatide up to 20 μg. Although delivery of FRCs is simplified by the use of a single pen 
injection, clear instructions and education is necessary in order to minimize potential 
medication errors in the clinical-care setting.  
Studies assessing FRCs of GLP-1 RA and insulin currently in development are 
summarized in Table 2. In the DUAL-I study (insulin-naïve patients with T2DM inadequately 
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controlled with metformin ± pioglitazone), IDegLira (insulin degludec [IDeg] and liraglutide 
[Lira]) was non-inferior to basal insulin degludec in terms of HbA1c reduction (decreases in 
HbA1c of –1.9% versus –1.4% [insulin degludec] but with more patients achieving the 
glycaemic target [HbA1c <7% (53 mmol/mol)] at equivalent insulin doses [81% vs 65%]). 
IDegLira was superior to the GLP-1 RA component liraglutide when administered alone 
(decrease in HbA1c of –1.3% with 60% of patients achieving their glycaemic goal). 
Furthermore, a greater proportion of patients achieved glycaemic targets without weight gain 
or hypoglycaemia with IDegLira (36%) compared with insulin degludec alone (14%).52 In 
DUAL-II, patients with T2DM previously treated with basal insulin plus metformin ± 
sulphonylureas/glinides, IDegLira achieved superior glycaemic control to insulin degludec 
alone (–1.9% versus –0.9%, respectively), with 60% of patients reaching glycaemic targets 
compared with 23% with insulin degludec.52,53 Again, a greater proportion of patients achieved 
glycaemic targets without weight gain or hypoglycaemia with IDegLira (40%) compared with 
insulin degludec (8.5%). The additional Phase IIIb DUAL trials (DUAL III–VI) have investigated 
IDegLira in increasingly difficult-to-treat T2DM patient populations, including patients who had 
failed basal insulin therapy despite unlimited titration (e.g. for the fully published trials to date, 
DUAL-III reported decreases in HbA1c of –1.3% [IDegLira] vs –0.3% [liraglutide or exenatide]; 
DUAL-V reported HbA1c decreases of –1.8% [IDegLira] vs –1.1% [insulin glargine] with 39% 
vs 12% of patients, respectively, achieving target HbA1c without weight gain or 
hypoglycaemia; DUAL-VI reported decreases in HbA1c from 8.2% to 6.1% [IDegLira once-
weekly titration] and from 8.1% to 6.0% [IDegLira twice-weekly titration] with approximately 
90% patients achieving target HbA1c, again without weight gain or hypoglycaemia).77  
In a proof-of-concept study, iGlarLixi was shown to be non-inferior to iGlar in patients 
continuing metformin treatment.78 This was followed by the LixiLan-O trial (insulin-naïve 
patients with T2DM inadequately controlled with metformin ± a second oral glucose-lowering 
drug), in which a higher proportion of patients receiving iGlarLixi (74%) achieved HbA1c <7% 
REVIEW ARTICLE 
 
18 
 
(53 mmol/mol) compared with insulin glargine 100 U (59%) or lixisenatide (33%) alone; 
respective reductions in HbA1c were –1.6%, −1.3%, −0.9%. A total of 32%, 19% and 27% of 
patients, respectively, achieved target HbA1c, without increasing the risk of hypoglycaemia or 
weight gain. Furthermore, iGlarLixi demonstrated lower GI side effects compared with 
lixisenatide (9.6% [nausea] and 3.2% [vomiting] vs 24% [nausea] and 6.4% [vomiting], 
respectively).69 In LixiLan-L, which comprised difficult-to-treat patients (uncontrolled glycaemia 
with basal insulin ± up to two oral glucose-lowering agents), similar efficacy and safety results 
were observed to those of LixiLan-O (target HbA1c was achieved in 55% [iGlarLixi] and 30% 
[iGlar] of patients; reductions in HbA1c were –1.1% and –0.6%; and 20% and 9% of patients 
reached the composite endpoint, respectively).68 Both iGlarLixi and IDegLira mitigate the 
weight gain seen with insulin, with rates of hypoglycaemia similar to those observed with the 
basal insulin component of the combination. Both IDegLira and iGlarLixi (60 U glargine and 20 
μg lixisenatide) were recently approved by the US Food and Drug Administration;79,80 IDegLira 
is approved in Europe. 
As expected, GI episodes (nausea and vomiting) were the most common adverse 
events reported by participants receiving FRCs, although the overall incidence was lower when 
compared with the GLP-1 RA component alone.52,53,68,69,78 This improved GI tolerability may be 
due to the slower release of the GLP-1 RA component in the FRC formulation in parallel with 
the up-titration of the insulin dose guided by the FPG response.  
Pen devices utilized for FRCs slow titration and facilitate individualization. For example, 
iGlarLixi’s dual pen system delivers insulin glargine and lixisenatide in two different ratios and 
offers a wider range of insulin doses than would be possible with a single pen, while retaining 
lixisenatide at the maximum-allowed daily dose; in the US, where iGlarLixi is only indicated for 
patients already taking basal insulin, a single pen (range 15–60 U) is available. Furthermore, a 
major decrease in insulin dose is not a limitation when switching to iGlarLixi, as patients on 
basal insulin have different iGlarLixi starting doses available to them depending on their 
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previous insulin requirement. However, with IDegLira, which is indicated for patients 
uncontrolled on either basal insulin or liraglutide (dose: up to 50 U insulin degludec and 1.8 mg 
liraglutide), some patients switching from insulin alone may need to start with a significant 
insulin dose reduction that could result in a longer time needed to achieve optimal treatment. 
Therefore, for both FRCs, labelling and instructions need to be very clear.  
The labelling for iGlarLixi states that in those patients inadequately controlled on <30 U 
basal insulin or on 20 μg lixisenatide, the recommended initial dose is 15 U (15 U iGlar/5 μg 
Lixi) once daily. The starting dose of iGlarLixi increases to 30 U (30 U iGlar/10 μg Lixi) once 
daily in patients inadequately controlled on 30–60 U basal insulin. IDegLira may be added to 
existing OADs with a recommended starting dose of 10 U insulin degludec and 0.36 mg 
liraglutide as part of a 10-dose step schedule, as required, with a reduction in sulphonylurea 
therapy to be considered to lower the risk of hypoglycaemia. When transferring from basal 
insulin only, the recommended initial dose is 16 U insulin degludec and 0.6 mg liraglutide with 
the option of 16 incremental dose steps. 
 
4 │ IMPLICATIONS 
Initiation of basal insulin early in T2DM, and using an FRC with a GLP-1 RA, provides a new 
therapeutic approach for second- or third-line therapy in the management algorithm of patients 
with T2DM, as FRCs have been shown to retain similar efficacy to free combinations.52,53,68,69,78 
It is well recognized that clinical inertia in T2DM leads to suboptimal glycaemic control 
with a delay in the escalation of therapy and the introduction of insulin due to fear of injections, 
the risk of hypoglycaemia, weight gain as well as the need for more SMBG.81 The more recent 
availability of GLP-1 RAs offers an alternative to insulin with equivalent glycaemic control, with 
the added advantage of weight loss and a low risk of hypoglycaemia in the absence of a 
sulphonylurea but with increased GI side effects, which, fortunately, are transient in the 
majority of patients. If increasing the dose of basal insulin is not an option and the earlier 
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introduction of a GLP-1 RA fails to achieve the required glycaemic target, then the combination 
of the two therapies becomes the next logical step. The recently available FRCs, iGlarLixi and 
IDegLira, provide a proven alternative to the free combinations52,53,68,69 while minimizing the 
adverse effect profiles of the two components. While sequential treatment is common practice, 
this alternative approach using an FRC has several advantages, including the likelihood of 
improved adherence by reducing administration burden with once versus multiple daily 
injections. However, it must be acknowledged that there are currently no studies directly 
comparing sequential treatment with earlier FRC use.  
Failure to attain glycaemic control has implications for patients, healthcare 
professionals and healthcare systems due to the increased risk of micro- and macrovascular 
complications associated with diabetes. Currently, only a third of people with T2DM achieve 
and maintain their target HbA1c level, and it is expected that the number of T2DM cases will 
dramatically increase over the coming decades, with the potential for a substantial negative 
impact on medical costs and healthcare resources.82 Achieving good glycaemic control in an 
attempt to avoid complications is, therefore, paramount but the hurdles are not insignificant. 
Prompt treatment with insulin and GLP-1 RA offers the opportunity of achieving glycaemic 
targets at an early stage of T2DM, which could potentially modulate the disease process and 
lower the rate of progression, thereby reducing the risk of complications and improving the 
individual’s quality of life.83 It is important to note that when comparing second-line treatment 
strategies in patients with T2DM and inadequate control on metformin alone, GLP-1 RAs were 
associated with a discounted incremental benefit of 0.10 and 0.25 quality-adjusted life years 
(QALYs) compared with DPP-4 inhibitors and Neutral Protamine Hagedorn insulin, 
respectively.83 Liraglutide has been shown to be cost effective compared with the DPP-4 
inhibitor, sitagliptin, added to metformin, with an incremental cost-effectiveness ratio below 
$50,000 per QALY gained.84 Using a medical economic model, lixisenatide was also 
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considered a cost-efficient therapy when compared with bolus insulin, with benefits in terms of 
QALYs gained and a reduction in lifetime healthcare costs.85 
The rationale for developing FRCs of basal insulin and GLP-1 RAs is scientifically valid, 
allowing the introduction of complementary therapies for improved outcomes with a lower risk 
of adverse events at any stage in the treatment algorithm.51 Importantly, the FRCs offer a real 
opportunity of introducing these therapies at an earlier stage in the disease process when, 
arguably, the greatest benefit will accrue.37,45 FRC delivery devices that allow slow titration 
according to clinical response and tolerance can substantially reduce the GI side effects of 
GLP-1 RAs as well as the risk of hypoglycaemia. This change in approach to treatment should 
reduce the impact on patients and healthcare resources alike. However, further studies are 
needed to support this proposed change to the T2DM treatment paradigm, and clear 
instructions will be required as to when and how to initiate and optimize FRCs in future 
guidelines. This shift reflects the aspiration of tailoring treatment to patients’ needs to maximize 
glycaemic control safely and effectively alongside improved quality of life. 
To be successful, this proposed change to the current treatment paradigm will require 
adequate education in order to realize the full benefits of the early introduction of insulin 
therapy and GLP-1 RAs in the form of FRCs.30-32,81,86 The ability to self-titrate FRCs in a similar 
manner to basal insulin, but with no additional risk of hypoglycaemia and/or weight gain, is a 
clear benefit. Also, FRCs could offer the potential to reduce the time taken to achieve good 
glycaemic control and modulate the disease process, which may reduce the burden on 
associated healthcare resources and result in cost benefits. 
 
5 │ CONCLUSIONS 
Poor glycaemic control underscores the limitations of current treatment options and algorithms 
advocated in management guidelines. An unacceptably high proportion of people with T2DM, 
despite the many therapeutic options available, fail to reach their glycaemic targets due to a 
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combination of factors, including poor adherence to therapy and clinical inertia from healthcare 
professionals. This review suggests a new treatment paradigm based around the early 
introduction of insulin and the rationale for a combination therapy of insulin plus a GLP-1 RA in 
the form of an FRC. This may facilitate the likelihood of achieving and sustaining good 
glycaemic control with fewer side effects and better adherence. Improving clinical outcomes 
and controlling resource use in the management of people with T2DM is imperative especially 
as the demand for treatment continues to grow. Further studies are required to explore the 
clinical advantages, limitations and best ways to utilize this proposed new paradigm in the 
management of T2DM. 
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FIGURE 1 Composite of HbA1c (A), FPG (B), body weight (C) and 2-hour PPG changes with 
lixisenatide.  
 
Lixisenatide: modified intent-to-treat populations. Week 24 data are last observation carried forward 
(GetGoal-L,
54
 GetGoal-L Asia
70
 and GetGoal Duo-1
55
).  
Patient populations enrolled in each lixisenatide trial: GetGoal-L (patients inadequately controlled on 
basal insulin); GetGoal-L-Asia (Asian patients inadequately controlled with basal insulin with/without 
sulphonylurea); GetGoal Duo-1 (insulin-naïve patients inadequately controlled with OADs). 
CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; LS, least squares; 
OAD, oral anti-diabetic drug; PPG, postprandial plasma glucose; SE, standard error 
*After a standardized liquid breakfast meal test (Ensure Plus). 
 
 
 
 
FIGURE 2 Composite of HbA1c (A), FPG (B) and body weight (C) changes with liraglutide in 
combination with basal insulin.104,105 
 
Modified intent-to-treat populations. *26-week study; 
†
16-week study; 
‡
study conducted in Japanese 
patients with low body mass index at enrolment. CI, confidence interval; FPG, fasting plasma glucose; 
HbA1c, glycated haemoglobin. Standard errors/standard deviations were not reported in the text of 
these studies but were reported in corresponding line graphs. 
